Trial · NCT07885319
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
NCT07885319, Phase 1, Phase 2, Recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma. Trials, record NCT07885319. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885319
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
- NCT number
- NCT07885319
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 78 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Malignant Pleural Mesothelioma, Advanced
- Interventions
- Ivonescimab Combined With Chemotherapy
- First posted
- 2026-10-21
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose-Limiting Toxicities in Phase 1b | From the first dose through Day 28. | Incidence of protocol-defined dose-limiting toxicities during the Phase 1b dose-limiting toxicity evaluation period. |
| Primary | Objective Response Rate | From the first dose through the last available tumor response assessment, up to 24 months. | Proportion of participants with a best overall response of complete response or partial response according to modified Response for malignant pleural mesothelioma. |
| Secondary | Treatment-Related Adverse Events | From the first dose through the last available safety assessment, up to 24 months. | Incidence and severity of treatment-related adverse events according to the Common Terminology Criteria for Adverse Events, version 5.0. |
| Secondary | Disease Control Rate | From the first dose through the last available tumor response assessment, up to 24 months. | Proportion of participants with a best overall response of complete response, partial response, or stable disease according to modified Response Evaluation Criteria in Solid Tumors for malignant pleural mesothelioma. |
| Secondary | Progression-Free Survival | From the first dose until disease progression or death from any cause, assessed up to 24 months. | Time from the first dose of study treatment to the first documented disease progression or death from any cause, whichever occurs first. |
| Secondary | Overall Survival | From the first dose until death from any cause, assessed up to 24 months. | Time from the first dose of study treatment to death from any cause. |
| Secondary | Duration of Response | From the first documented complete response or partial response until disease progression or death from any cause, assessed up to 24 months. | Time from the first documented complete response or partial response to the first documented disease progression according to modified Response Evaluation Criteria in Solid Tumors for malignant pleural mesothelioma or death from any cause, whichever occurs first. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885319
GET https://conductscience.org/api/trials/v1/NCT07885319/registered